Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Share-based Compensation (2024 - 2025)

Historic Share-based Compensation for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $1.1 million.

  • Xilio Therapeutics' Share-based Compensation fell 2865.31% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year change of. This contributed to the annual value of $6.4 million for FY2024, which is 1284.2% down from last year.
  • According to the latest figures from Q3 2025, Xilio Therapeutics' Share-based Compensation is $1.1 million, which was down 2865.31% from $1.4 million recorded in Q2 2025.
  • Xilio Therapeutics' Share-based Compensation's 5-year high stood at $1.8 million during Q1 2024, with a 5-year trough of $1.1 million in Q3 2025.